2014
DOI: 10.1590/abd1806-4841.20143058
|View full text |Cite
|
Sign up to set email alerts
|

Vulvar vitiligo-like depigmentation and multiple halos of hypomelanosis at the trunk following treatment with imiquimod 5% cream for vulvar condylomata: casual or related events?

Abstract: A 25-year-old Caucasian female with multiple genital warts involving the vulvar area was treated with imiquimod 5% cream. During follow-up the patient developed areas of hypopigmentation at the site of application of imiquimod cream and areas of hypomelanosis around multiple preexisting nevi of the trunk. At 18 months follow-up genital depigmentation persisted and halo nevi of the trunk were still present. Different mechanisms of imiquimod-induced depigmentation have been reported. Halo nevi are considered exp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 7 publications
0
4
0
Order By: Relevance
“…In the literature, imiquimod application has been reported to cause depigmentation via different mechanisms of action, including postinflammatory depigmentation, necrosis or apoptosis of melanocytes, and immune-mediated vitiligo-like reactions [ 5 ]. One reason for the presence of those depigmented lesions after topical imiquimod application is that the cream could induce local melanocyte apoptosis [ 12 ], which was observed by TUNEL assay, by Hoechst 33258 staining, and by measuring mitochondrial membrane potential in melanocytes [ 8 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…In the literature, imiquimod application has been reported to cause depigmentation via different mechanisms of action, including postinflammatory depigmentation, necrosis or apoptosis of melanocytes, and immune-mediated vitiligo-like reactions [ 5 ]. One reason for the presence of those depigmented lesions after topical imiquimod application is that the cream could induce local melanocyte apoptosis [ 12 ], which was observed by TUNEL assay, by Hoechst 33258 staining, and by measuring mitochondrial membrane potential in melanocytes [ 8 ].…”
Section: Discussionmentioning
confidence: 99%
“…Imiquimod (Aldara®) (2.5, 3.75, and 5%) is a commercially available topical cream. It is currently approved by the US Food and Drug Administration (FDA) for use as a topical treatment for biopsy-confirmed small superficial basal cell carcinoma measuring up to 2 cm in its greatest diameter over the neck, trunk, or extremities (excluding the hands and feet) [ 1 ], nonhyperkeratotic nonhypertrophic actinic keratoses over the face and/or scalp [ 2 , 3 ], and external genital and perianal warts (condylomata acuminata) in adults [ 4 , 5 ]. In condylomata acuminata, which is considered to be a sexually transmitted disease, it is approved to be used as a 5% cream three times weekly for up to 16 weeks, or as a 3.75% cream daily for up to 8 weeks [ 6 ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Similarly, Alatabani et al [ 31 ] reported a case of a patient who experienced depigmentation at both the treated and nontreated sites after topical treatment of genital warts with imiquimod 5% cream. Serra et al [ 36 ] reported an interesting case in which, in addition to hypopigmentation at the sites of application, the patient developed halos of hypomelanosis around multiple preexisting melanocytic nevi of the trunk following topical administration of imiquimod for vulvar condylomata. In these reports, patients denied using any topical treatment other than imiquimod.…”
Section: Rare Imiquimod-associated Cutaneous Side Effectsmentioning
confidence: 99%